It seems that three covid 19 shots will not be enough to stop the Omicron covid variant. This is what Ugur Sahin, the CEO of vaccine developer BioNTech.
“We must be aware that even triple-vaccinated are likely to transmit the disease,” he told French daily Le Monde.
He added this:
“It is obvious we are far from 95 percent effectiveness that we obtained against the initial virus.”
Deseret.com notes that Sahin said vaccine efficacy has been dropping against the Omicron covid variant.
It’s important to note the fact that this is a sign that the vaccines aren’t enough, according to Euro News.
“There will be a loss of effectiveness against Omicron over time, it’s very likely, but it’s still to be measured how quickly. I will not base predictions on preliminary laboratory data but on real-life data, which is much more appropriate,” Sahin said.
He also said that this is the main reason for which consistent testing is important for monitoring the spread of the virus.
Covid studies reveal interesting news about treatments
There are more and more predictions about the path that the pandemic will be taking in the near future. Now, it’s been revealed that brand new studies are addressing the efficiency of AstraZeneca’s monoclonal antibody drugs.
It’s been just revealed that the drug is effective against the covid 19 variant Omicron, according to a new report.
“The company’s EVUSHELD retains neutralization activity against omicron, according to ‘live’ virus neutralization data from both University College Oxford and Washington University School of Medicine,” ABC News reported.
The online publication Daily Wire revealed that AstraZeneca’s treatment was authorized on December 8 but used to prevent covid 19 “among people who are immune compromised, or people who are allergic to vaccine components. It is not authorized as a way to treat COVID-19 among people who have already tested positive,” ABC reported.